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The f3-adrenergic antagonist timolol has been shown to 
be an effective agent in decreasing intraocular pressure (IOP) 
in both experimental animals and humans. The mechanism by 
which this is achieved, however, is not understood. Many 
feel that timolol decreases IOP by blocking 3-adrenergic 
receptors in the ciliary processes, leading to a decrease 
in formation of aqueous humor, while others believe that 
timolol effects a decrease in IOP by a mechanism other than 
(3-adrenergic blockade. Those who support the latter proposal 
cite as evidence the fact that timolol has been shown to 
act as a 3-adrenergic antagonist at low concentrations, but 
that higher concentrations are needed to cause a decrease 
in IOP. 
The purpose of this study was to estimate the reten¬ 
tion of timolol in the ocular tissues of the New Zealand 
White rabbit after topical application. Two different doses 
of timolol were used; one that was capable of decreasing 
IOP, and the other incapable of decreasing IOP. If timolol 
were in fact decreasing IOP by 3-adrenergic antagonism, 
the concentrations of timolol in the ciliary processes after 
topical application of both concentrations should be close 
to Kj for timolol binding to the 3-adrenergic receptors in 
this tissue; however, if this were not the mechanism, then 
the concentrations of timolol in the ciliary processes should 
be much higher than K^. 
It was demonstrated that the concentration of timolol 
in the ciliary processes exceeded the concentration needed 
2 3 
to effect 3-adrenergic blockade by a factor of 10 to 10^, 
even when the dose of timolol used was incapable of lowering 
IOP. These finding's support the theory that timolol decreases 
IOP by a mechanism other than 3-adrenergic blockade. 
Also, in this thesis, the literature concerning the 
effects of adrenergic agents upon aqueous humor dynamics 
and IOP is reviewed. 
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INTRODUCTION 
Drugs influencing the adrenergic receptors of the eye 
have been used in treating glaucoma since the early 1920s 
when the Berlin ophthalmologist Hamburger reported that 
subconjunctival injection of epinephrine caused a signifi¬ 
cant decrease in intraocular pressure (I0P) in patients 
1 2 
with acute and chronic glaucoma. ’ Earlier reports by 
3 4 < 
Erdmann, Knapp, and Daner demonstrate the extensive 
early interest in epinephrine as a treatment for mlaucoma. 
The separation of the adrenergic system into the a and f3 
£ 
components by Ahlquisx resulted in new attempts to under¬ 
stand the role of the adrenergic system in regulating I0P. 
7 
In the 1950s, Weekers et al. showed that the 3-adrenergic 
agonist isoproterenol, applied topically to the eye, pro¬ 
duced a decrease in I0P comparable to that caused by epi¬ 
nephrine. Since then, considerable effort has been made 
to understand the mechanism of the adrenergic influences 
on I0P. 
Early studies investigated the role of the adrenergic 
system in controlling I0P by excising the cervical sympathet¬ 
ic nervous system in rabbits and then monitoring I0P and 
outflow facility. The earliest studies by Linner and 
g Q 10 
Prijot ,y and Lieb et al. showed that preganglionic cerv¬ 
ical sympathectomy had no effect on I0P, inflow, or facil¬ 
ity of outflow, but that excision of the superior cervical 
ganglion resulted in a marked decrease in I0P 24 hours 
after the procedure, followed by a return to normal. 
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Constant pressure perfusion studies in these animals seemed 
to show that the outflow facility remained similar to that 
found in the control eyes. This led to the conclusion that 
the decrease in IOP after ganglionectomy was the result 
of a marked decrease in the formation of aqueous humor. 
On the other hand, other studies of the ganglionect- 
omy effect1 demonstrated an increase in facility assoc¬ 
iated with the observed decrease in IOP. Langham and 
1112 
Taylor ’ noted that an additional decrease in the IOP 
could be achieved by the administration of acetazolamide, 
a carbonic anhydrase inhibitor which decreases the rate of 
19 
aqueous formation, demonstrating that secretion of aqueous 
humor had previously been present. These findings suggested 
that an increase in outflow facility rather than the pre¬ 
viously proposed decrease in aqueous humor secretion was 
the mechanism by which ganglionectomy caused the observed 
reduction in IOP. 
12 
Sears and Barany, J by directly monitoring IOP by mtra- 
cameral cannulation and manometry, documented that the a- 
adrenergic antagonist dibenamine decreased outflow facility, 
while ganglionectomy increased outflow facility. They 
concluded that the decrease in IOP at 24 hours after gan¬ 
glionectomy was largely due to the release of a-adrenergic 
neurotransmitters from the degenerating adrenergic nerve 
endings. This conclusion was supported by the further 
14 15 16 
findings of Barany, Sears and Sherk, ’ Rosser and 
17 18 
Sears, r and Eakins and Eakins, who together demonstrated 
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that gangionectomy resulted in a loss of norepinephrine 
from the iris and ciliary body, apparently secondary to the 
degeneration of adrenergic nerve endings in these tissues. 
Norepinephrine, an a-adrenergic agonist, caused an increase 
in outflow facility upon release from the nerve endings, 
most likely by stimulating a-adrenergic receptors in the 
trabecular meshwork. The a-adrenergic antagonists diben- 
13 l4,l6 . 
amine and phenoxybenzamme inhibited the norepmeph- 
rine-induced increase in outflow facility. Also, prior 
depletion of catecholamine stores in the tissue by reserpine 




Hendley and Crombie showed that propranolol, a (3- 
adrenergic antagonist, had no effect on the decrease in I0P 
or the increase in outflow facility in eyes of ganglionec- 
tomized animals, while phentolamine, an a-adrenergic antag¬ 
onist, blocked both effects. This led to the conclusion 
that a-adrenergic but not P-adrenergic receptors were in¬ 
volved in regulating outflow facility. 
In other studies, various a- and P-adrenergic agonists 
were administered intravenously, intravitreally, subcon- 
junctivally, or topically to rabbits in all possible com- 
21 
binations and at every conceivable dose. Eakms treated 
rabbits intravitreally with epinephrine, norepinephrine, 
and isoproterenol. These studies revealed that epinephrine 
in small doses decreased I0P without affecting outflow 
facility, while larger doses of epinephrine decreased I0P 
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and also slightly increased outflow facility. Norepinephrine 
consistently decreased IOP and increased facility. Isopro- 
terenol usually resulted in a decrease in IOP without chang¬ 
ing outflow facility; however, large doses of isoproterenol 
were observed to increase outflow facility. Eakins concluded 
that a-adrenergic stimulation resulted in increased outflow 
facility, that isoproterenol caused a decrease in IOP prob¬ 
ably by decreasing aqueous humor formation, and that small 
doses of epinephrine behaved very similarly to isoproterenol 
in the rabbit; in other words, like a ^-adrenergic agonist. 
22 
Further studies by Eakins and Ryan supported the 
concept that a-adrenergic agonists lower IOP by increasing 
outflow facility. Phentolamine was shown to decrease signif¬ 
icantly the effect of norepinephrine upon IOP and outflow 
facility. The increase in facility of outflow caused by 
laree doses of isoproterenol was completely inhibited by 
phentolamine. This supported the earlier conclusion of 
23 
Butterworth v that, at high doses, isoproterenol was capable 
24 
of stimulating a-adreneraic receptors. Ahlquist has also 
reported that isoproterenol possesses a-adrenergic stimula¬ 
tory properties. Work published at the same time by 
Gnadinger and Barany2^ also demonstrated that isoproterenol 
led to an increase in outflow facility, and Gnadinger con¬ 
cluded that 3-adrenergic stimulation led to increased facil- 
ity. Sears and Barany J also demonstrated that dichloro- 
isoproterenol (DCI), a ^-adrenergic antagonist with partial 
3-adrenergic stimulatory properties, also increased outflow 
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facility. However, the doses of isoproterenol used by 
Gnadinger were quite high; higher, in fact, than the doses 
at which Eakins had earlier reported that isoproterenol 
22 
apparently possessed mild a-adrenergic agonistic behavior. 
Because of these conflicting findings, the role of pure 3- 
adrenergic stimulation in increasing outflow facility in 
rabbits is unclear. 
In summary, these studies have demonstrated that, in 
the rabbit, a-adrenergic stimulation causes an increase in 
outflow facility and a decrease in IOP, while ^-adrenergic 
stimulation causes a decrease in IOP and may also increase 
7 21 
outflow facility. Weekers et al. and Eakins postulated 
that the 3-adrenergic-induced decrease in IOP may have been 
secondary to a decrease in aqueous humor formation. Other 
studies in rabbits with adrenergic agonists support this 
hypothesis that 3-adrenergic stimulation most likely caused 
a decrease in formation of aqueous humor, leading to a 
. 26-30 
decrease m IOP. ^ 
29 
Langham and Diggs demonstrated that salbutamol, a 
specific 3s-adrenerfic agonist, when applied topically or 
injected intravitreally in rabbit eyes, led to a decrease 
in IOP treater than that observed with isoproterenol. Their 
three studies, ' when considered together, indicate that 
the a-agonist-induced decrease in IOP is delayed, with min¬ 
imal pressures achieved at 4 to 6 hours, while the decrease 
in IOP induced by isoproterenol or salbutamol is of rapid 
onset, with maximal decreases in IOP noted at 1 to 2 hours. 
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The fact that the onset of the decrease in IOP is so differ¬ 
ent for a- and f3-adrenergic stimulation supports the conclu¬ 
sion that a- and 3-adrenergic stimulation lead to a decrease 
in IOP via different mechanisms. 
The studies of Potter and Rowland^ again demonstrated 
the effectiveness of salbutamol in decreasing IOP. Also, 
the f3 2-adreners:ic agonists isoetharine, metaproterenol, 
terbutaline, carbuterol, quinterenol, and sulfonterol all 
decreased IOP; the maximum decrease occured between ■§ and 
2 hours after topical application. The selective ct-adren- 
ergic agonists norepinephrine and phenylephrine showed a 
delayed decrease in IOP, with minimal IOP achieved at 4 
32 
hours. Rowland and Potter-^ also demonstrated that the 
£2-adrenergic agonist reproterol was effective in blunting 
the water-load-induced increase in IOP in rabbits, while 
the selective ^-adrenergic agonist tazolol was not. The 
results of these studies indicate that stimulation of a- 
adrenergic receptors leads to a decrease in IOP by increasing 
facility, while stimulation of (3 (and more specifically 32) 
adrenergic receptors results in a decrease in IOP by decreas¬ 
ing formation of aqueous humor. 
The effects of adrenergic stimulation upon IOP and 
outflow facility in rabbit eyes are summarized in Table 1. 
Barany-^ perfused the anterior chamber of vervet mon¬ 
keys with fluid, constantly monitoring fluid flow rate and 
pressure, and noted an increase in outflow facility but no 




Billv demonstrated m vervet monkeys that epinephrine 
caused an increase in IOP at 1 hour that had disappeared 
by 2 hours, along with a significant decrease in the flow 
rate of aqueous humor, and an increase in facility. In a 
35 
later study, Bill demonstrated that isoproterenol increased 
aqueous humor formation by J0% and facility of outflow by 
55%‘ Both effects were abolished by propranolol. 
It is dangerous to generalize the physiology of aqueous 
humor dynamics in rabbits and monkeys to man. Therefore, 
the studies that have been performed with human subjects 
7 
are of particular interest. In man, Weekers et al. demon¬ 
strated that topical epinephrine led to a decrease in IOP 
and aqueous humor formation, and that isoproterenol caused 
a decrease in IOP comparable to that caused by epinephrine. 
36 37 
Ross and Drance^ also demonstrated that topical isopro¬ 
terenol led to a dose-related decrease in IOP in patients 
with elevated IOP; however, this effect was lost after 
treatment over a two week period. Three of the four patients 
whose outflow facility was measured showed a decrease in 
facility. No increase in outflow facility was noted. This 
suggests that isoproterenol decreased aqueous formation. 
Oaasterland et al.-^ investigated the effects of el¬ 
and ^-adrenergic stimulation on aqueous dynamics in the 
eyes of healthy young men and demonstrated that isoproter¬ 
enol applied topically caused a decrease in IOP and aqueous 
flow without affecting outflow facility. Norepinephrine 
had no effect on IOP or outflow facility but did increase 
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the flow rate of aqueous, although this increase was not 
statistically significant. Epinephrine caused decreases 
in IOP and aqueous humor flow and increased outflow facil¬ 
ity; however, the increase in outflow facility was not 
statistically significant. Other studies2^’have supported 
the conclusions of Gaasterland concerning isoproterenol and 
epinephrine, but have demonstrated that norepinephrine does 
decrease IOP and increase outflow facility. Paterson and 
40 
Paterson have further demonstrated that salbutamol is 
31 
effective m decreasing IOP in humans as well as m rabbits. 
Additional studies have demonstrated that epinephrine 
. . . . . 4i-48 
m humans does in fact increase outflow facility, m 
33 
agreement with the findings m monkeys by Barany-^ and 
34 43 
Bill. Krill et al. ^ reported an increase in outflow 
facility in only some of the patients in whom epinephrine 
44 
caused a decrease m IOP. Kronfeld reported an increase 
in outflow facility on the day of treatment with epineph¬ 
rine and on the following day. He explained the observed 
decrease in IOP as being caused by the increase in outflow 
. . . 49 
facility. Thomas and Epstein also reported that topical 
epinephrine in humans caused an increase in facility of 
outflow. This increase in outflow facility was effectively 
blocked by timolol, a (3-adrenergic antagonist. Sears^0’-^ 
summarized these actions of epinephrine by defining three 
phases of action. During the early phase, occurring immed¬ 
iately after instillation of epinephrine, a decrease in IOP 
occurs which is secondary to both a decrease in aqueous 
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humor inflow (probably a result of decreased blood flow 
to the ciliary processes) and an increase in outflow facil¬ 
ity; both effects are probably mediated by a-adrenergic 
receptor stimulation. During the intermediate phase, last¬ 
ing for several hours after instillation, the increase in 
facility becomes the more important factor; this process is 
mediated in part by a ^-adrenergic receptor. Later, over 
a period of days to months, there is a progressive increase 
in outflow facility. 
48 
Townsend and Brubaker demonstrated with a fluoro- 
photometric technique that epinephrine caused an early 
increase in aqueous humor formation. These photofluoro- 
metric results of aqueous humor formation differ signif- 
7 . 52 
icantly from previously studies. Weekers et al. and Nagataki 
demonstrated that epinephrine caused a decrease in the rate 
of loss of fluorescein from the anterior chamber, indicating 
a decrease in the rate of aqueous humor formation. A pos¬ 
sible explanation for this apparent discrepancy is the time 
at which the measurements for determining aqueous humor 
formation were made. Weekers measured fluorescein disap¬ 
pearance 24 hours after instilling epinephrine into the 
eye, and estimated a decrease in aqueous humor formation 
of 30$. Nagataki found a suppression of aqueous formation 
of 20$ at 10 hours. Townsend's data was taken earlier 
after epinephrine instillation. It has been reported that 
epinephrine can cause a transient, early increase in I0P 




in I0P. The mechanism of this transient increase is 
unclear, but may be mediated by a-adrenergic stimulation, 
as this transient increase has also been noted to occur in 
• • 31 
eyes treated with norepinephrine and phenylephrine. If 
this increase in I0P were caused by a transient increase 
in aqueous humor formation, it would explain the apparently 
contradictory findings of these reports, and still remain 
consistent with the other experimental findings concerning 
epinephrine. 
The effects of adrenergic stimulation upon aqueous 
humor dynamics in the human eye as demonstrated by the 
previously discussed reports are summarized in Table 2. 
The molecular basis for the P-adrenergic-mediated 
decrease in I0P has recently been an area of much research. 
It had earlier been shown that stimulation of 3-adrenergic 
receptors results in activation of the enzyme adenyl cycl¬ 
ase, which catalyzes synthesis of adenosine 3'»5'-monophos¬ 
phate (cyclic-AMP), which, in turn, acts as a second messeng- 
33 54 
er within the cell. ^ Waitzman and Woods demonstrated 
the presence of a catecholamine-stimulated adenyl cyclase 
in the ciliary processes of rabbits. Further extensive 
work by Neufeld, Sears, and co-workers'"0 D demonstrated 
that epinephrine, norepinephrine, and isoproterenol, applied 
topically to rabbit eyes, all caused an increase in aqueous 
humor levels of cyclic-AMP, especially in the anterior 
chamber. A high correlation was found between the eleva¬ 
tion of cyclic-AMP and the decrease in I0P. Also, when 
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cyclic-AMP and dibutyryl cyclic-AMP were perfused through 
the anterior chamber, increases in outflow facility similar 
to those seen with epinephrine were observed. Perfusion 
with isotonic saline or with adenosine 5'-monophosphate, 
an inactive metabolite of cyclic-AMP, failed to produce a 
change in outflow facility. The authors concluded that 
these findings supported the view that catecholamines act¬ 
ivated adenyl cyclase by stimulating ^-adrenergic receptors, 
increased intracellular cyclic-AMP, and increased outflow 
facility. The same experiments were duplicated by Neufeld^ 
in the vervet monkey with similar results. Neufeld extended 
the study one step further by first injecting isoproterenol 
of epinephrine intracamerally, observing an increase in 
outflow facility, and then injecting cyclic-AMP and noting 
that no further increase in outflow facility occurred. This 
added further support to the conclusions of Sears and Neufeld. 
Cholera toxin is known to stimulate adenyl cyclase, 
and has been useful in studying the action of adenyl cyclase 
,. 60-62 . ^ i 63 
m various tissues. In studies by Gregory et al. 
6S 
and Sears et al., cholera toxin was used to study what 
effect the stimulation of adenyl cyclase would have upon 
I0P and aqueous flow. Intravitreal injection of small doses 
(0.02 - 2.0 |ig) of cholera toxin caused a remarkable decrease 
in ipsilateral ocular tension usually after 6 hours, without 
changing the I0P in the contralateral control eye. Intra¬ 
arterial infusion of 2 pg of cholera toxin via selective 
catheterization of the internal maxillary artery also led 
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to a decrease in IOP after 4 to 6 hours, and a $0% decrease 
in the rate of aqueous formation in the ipsilateral eyes. 
Intra-arterial infusion of saline had no effect on IOP. 
Ocular blood flow estimates made after infusion of cholera 
toxin indicated that blood flow to the anterior uvea in¬ 
creased as IOP fell, which ruled out the possibility that 
the decrease in aqueous humor formation was a result of 
decreased blood flow. Also, in vitro studies were conducted 
that demonstrated that incubation of ciliary processes with 
cholera toxin activated adenyl cyclase. A report published 
at the same time confirmed the findings of Gregory et al. 
that intravitreal cholera toxin results in a decrease in 
64 
IOP. The authors also reported an increase m outflow 
facility after intravitreal injection of cholera toxin, 
which supports earlier data that suggested that intracam- 
eral cyclic-AMP caused an increase in facility.^^ 
66 
Mishima et al. have studied the anatomic location 
of the binding sites for cholera toxin in rabbit eyes using 
fluorescein-labeled and horseradish peroxidase-labeled 
cholera toxin. In vitro incubations of ciliary processes 
with fluorescein-labeled cholera toxin demonstrated multi¬ 
ple binding sites along the inner nonpigmented epithelial 
layer. Intra-arterial infusions of horseradish peroxidase- 
labeled cholera toxin via the internal maxillary artery 
demonstrated a dense reaction product located between the 
apical plasma membranes of the pigmented epithelium and the 
nonpigmented epithelium. These findings are consistent 
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with an epithelial binding site for cholera toxin and with 
biochemical studies supporting the premise that 3-adren- 
ergic agonists decrease IOP by a cyclic-AMP mediated de¬ 
crease in aqueous humor secretion. 
67 68 
Radius and Langham ' and Boas et al. have questioned 
the importance of cyclic-AMP as a messenger involved in the 
catecholamine-induced decrease in IOP. Boas argued that in 
the case of epinephrine, aqueous humor cyclic-AMP is in¬ 
creased early after instillation; cyclic-AMP levels peak 
at 1 to 4 hours and decline to basal levels by 6 hours, 
but the decrease in IOP was not significant until 6 hours. 
Because of the discrepancies in the time association of 
elevated cyclic-AMP levels and decreased IOP, Boas concluded 
that the two were not related. He failed to take into 
account that the intracellular, not the aqueous humor, 
cyclic-AMP is the important factor, and the intracellular 
levels were not assessed. Also, as epinephrine may cause 
a transient increase in IOP, it is possible that this 
effect masks the early action of a 3-adrenergic mediated 
increase in cyclic-AMP which, in the absence of the early 
elevation in IOP (probably a-induced), would most likely 
have led to a decrease in IOP. It is interesting to note 
that pure 3-adrenergic agonists cause a significant decrease 
. 29 31 
m IOP at 1 to 2 hours, ’ which would correspond well 
to the time sequence of increased cyclic-AMP in the aqueous 
humor as reported by Boas. Boas also fails to consider 
that only minimal intracellular increases in cyclic-AMP 
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could be the trigger initiating a cascade of intracellular 
events leading to a delayed decrease in the IOP. Because 
of these considerations, the arguements of Boas are not 
credible. 
Much work has also been done in attempting to localize 
anatomically the adrenergic receptors of the eye. 
69 
Bhattacherjee showed that uptake of topical and intra- 
cameral [%Jnorepinephrine in the ocular tissues of rabbits 
is complete within 2 hours. Extensive uptake in the epi¬ 
thelium of the ciliary processes was observed, as well as 
in the dilator muscle of the iris and the ciliary body, 
indicating rich adrenergic innervation of these tissues. 
70 
Neufeld and Page identified a- and P-adrenergic 
receptors in preparations of rabbit iris-ciliary body by 
ligand binding techniques using [%]dihydroergocryptine 
and [^HDdihydroalprenolol (specific for a- and f3-adrenergic 
71 72 
receptors respectively). Lahav, Dafna, and co-workers 
injected 9-aminoacridinpropranolol, a fluorescent analog 
of propranolol into the risht internal carotid artery of 
rabbits and into the tail vein of rats, and observed up¬ 
take of the analog in the ciliary body, iris, and episcleral 
tissue at the limbus of the rat. Almost no fluorescence 
was present in the ciliary muscle, while the sphincter of 
the iris exhibited diffuse fluorescence. In the rabbit, 
fluorescence was present over both epithelial layers of the 
ciliary epithelium. Only a few fluorescent cells were 
seen in the stroma of the ciliary processes. No fluores- 
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cence was seen in the trabecular meshwork. 
73 74 
Bromberg, Gregory, and co-workers J demonstrated 
that the highly specific 3-adrenergic ligand [12^I]iodo- 
hydroxybenzylpindolol2^ ([^2^l]HYP) binds to a single set 
of receptor sites in rabbit ciliary processes. Binding 
A O £ 
of [ ^iIlHYP was inhibited by 3-adrenergic antagonists 
(1-alprenolol, d,1-propranolol, and 1-timolol) and a- and 
3-adrenergic agonists (1-isoproterenol and 1-norepinephrine) 
but not by an a-adrenergic antagonist (phentolamine). The 
authors concluded from these results that the [12^l]HYP 
binding site is a 3-adrenergic receptor. 
74 76 
Studies of the adenyl cyclase of rabbit and 
77 . . 
human ciliary processes showed that catecholamines dif¬ 
fered in their ability to activate the enzyme in the follow¬ 
ing order: isoproterenol > epinephrine > norepinephrine > 
phenylephrine. This sequence of sensitivity has been noted 
to be present in tissues with 3^-adrenergic receptors (vas¬ 
cular and bronchial smooth muscle), as opposed to 3i-adren- 
ergic receptors (cardiac and adipose tissue, and small 
ry O 7677 
intestine).' Stimulation by isoproterenol'''’'' and epi- 
74 
nephrine was inhibited by low doses of 3-adrenergic antag- 
74 
onists including timolol, but not by phenoxybenzamme 
or phentolamine.^ The selective 3^-adrenergic antagon¬ 
ists IPS 339 and H35/25 also inhibited isoproterenol- 
mediated stimulation of adenyl cyclase at low concentrations 
whereas, selective 3i-adrenergic antagonists (atenolol and 
practolol) were less effective.''7^’''72 Furthermore, selective 
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3--adrenergic agonists (zinterol and OPC 2009) were much 
more effective in stimulating adenyl cyclase from rabbit 
ciliary processes than a selective |3^.-adrenergic agonist 
(prenalterol). ^ 
The most interesting aspect of the studies by 
Nathanson' 'was the assay of adenyl cyclase in dispersed 
cell fractions. It was shown that the basal and isoproter¬ 
enol-stimulated adenyl cyclase specific activities were 
greater in the epithelial cell fraction, which contained 
both secretory and pigment cells, than in whole ciliary 
processes or the partially de-epithelialized vascular net¬ 
work . 
These studies support, by a more direct approach, the 
conclusions drawn by using other techniques: that 32- 
adrenergic receptors exist in the epithelial cells of the 
ciliary processes which, upon stimulation, activate aden¬ 
ylate cyclase . 
13 
Sears and Barany published the first report of an 
adrenergic antagonist decreasing I0P. Since that report, 
much work has been done that demonstrates that adrenergic 
antagonists decrease I0P. The a-adrenergic antagonists 
prazosin, labetalol, thymoxamine, and phenoxybenzamine 
28,80,81 
have all been shown to decrease I0P. However, 
other studies have shown that thymoxamine and phenoxybenz- 
8 0 82 8 3 
amine may not lower I0P under all circumstances. ’ ’ ^ 
3-adrenergic antagonists have been more extensively studied 
than the a-adrenergic antagonists, and also are effective 
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in decreasing IOP. The non-selective 3-adrenergic antag¬ 
onist propranolol has been reported to decrease IOP in 
32 8^-9^ 
rabbits and humans by a number of investigators. * 77 
Authors have variously reported that propranolol decreases 
outflow facility, 7 increases outflow facility, ^ and de¬ 
creases formation of aqueous humor. 
The non-selective 3-adrenergic antagonists oxprenolol, 
timolol, pindolol, butridine, DCI, alprenolol, and bupranolol 
13 oi q4-Q8 
have also been shown to decrease IOP. v 7 A study 
96 
by Bonomi and Steindler demonstrated a slight increase 
in outflow facility with pindolol, but the observed increase 
in facility was considered to be too small to account for 
the observed decrease in IOP. 
88 
Musini et al. demonstrated that the non-selective 
3-adrenergic antagonists lignocaine and INPEA, devoid of 
local anesthetic properties, did not decrease IOP, while 
d,1-propranolol, with local anesthetic properties, did de¬ 
crease IOP. They concluded that the local anesthetic prop¬ 
erties of propranolol were responsible for its effect in 
O rn 
decreasing IOP. However, Vale and Phillips ' demonstrated 
that d-propranolol, which is identicle to d,1-propranolol 
with respect to its membrane-stabilizing and anesthetic 
effects, but only l/60th as active in blocking 3-adrenergic 
receptors, ’ was not effective in decreasing IOP. 
Therefore, the conclusions of Musini were not supported. 
The selective 3i-adrenergic antagonists practolol, 
atenolol, metoprolol, sotalol, ICI 66082, and the selective 
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P2-adrenergic antagonist IPS 339 have all decreased IOP in 
92-Q4 101-108 
rabbits and humans. ^ Of these compounds, pindolol 
has only a slight membrane-stabilizing effect and no local 
96 
anesthetic effect, and practolol, timolol, sotalol, and 
atenolol are all devoid of both ef f ects . ^ ’ 101 ’ In 
spite of this, they are all capable of inducing significant 
decreases in IOP. In fact, Bonomi found that timolol and 
sotalol were the most active of the (3-adrenergic antagonists 
94 
tested in decreasing IOP. These studies again demonstrated 
that it was not the local anesthetic properties of the 
(3-adrenergic antagonists that were responsible for their 
ability to reduce IOP. 
Of the adrenergic antagonists named, only timolol has 
been approved by the FDA for use in treating glaucoma, and 
therefore, timolol is the most studied ocular hypotensive 
10 6 
antagonist. Timolol was first described by Hall1 as a 
potent P-adrenergic antagonist, several times more active 
than propranolol, and devoid of sympathomimetic, local 
107 94 
anesthetic, and membrane-stabilizing effects. Early 
studies of the effects of timolol in rabbits with a-chymo- 
trypsin-induced elevated IOP and in rabbits with normal 
98 
eyes by Vareilles et al. demonstrated a gradual and sus¬ 
tained fall in IOP in rabbits with a-chymotrypsin-induced 
elevations in IOP after treatment with 0.5$ and 1.5$ timolol 
solutions. The maximum decrease occurred at 210 minutes 
after instillation. Only marginal decreases in IOP in 
normal rabbit eyes treated with timolol were noted. 
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1 O R 
Studies in 15 normal humans by Katz et al. demon¬ 
strated that drops of 0.5%» 1.0%, and 1.5# timolol solution 
caused a significant decrease in IOP. Other studies have 
also demonstrated a decrease in IOP with topical timolol, 10<^_ 1 li4 
which is sustained over long periods with twice-daily 
111 
dosage. Decreases m IOP observed with timolol are ad¬ 
ditive with the decreases induced by both miotics and car¬ 
bonic anhydrase inhibitors, indicating that timolol prob¬ 
ably acts by some mechanism different than that by which 
111 112 
both of these drugs act. ’ 
Timolol has also been reported to cause an additional 
decrease in IOP over short periods when added to epinephrine 
115-117 . . 
therapy. An additive decrease m IOP has also been 
noted in rabbits with normal IOP treated with timolol plus 
epinephrine or norepinephrine, but not timolol plus isopro- 
118 49 
terenol. However, Thomas and Epstein have noted that 
the additive effect of timolol and epinephrine in humans 
lasts for approximately 2 weeks, and at 8 weeks no signif¬ 
icant additive decrease in IOP remains. Unfortunately, 
this study does not have a control group treated only with 
timolol or epinephrine for the 8 week duration of the study, 
and the findings are therefore difficult to interpret. 
Zimmerman et al.,^^ Boger et al.,^^ and others'*-^ ’ ’ 
119-121 
demonstrated that timolol lowered IOP without in¬ 
creasing outflow facility, even after long-term treatment. 
These investigators concluded that timolol acts by decreas¬ 




studies in humans, Coakes and Brubaker and Yablonski et 
123 
al. v demonstrated that the timolol-induced decrease in 
I0P was associated with a decrease in aqueous humor flow. 
Coakes measured a minimum decrease of 13%, a maximum of 
48%, and a mean decrease of 3^% in aqueous humor flow. 
Both reports concluded that the decrease in aqueous humor 
formation was most likely responsible for the decrease in 
I0P. This is also apparently the mechanism of timolol's 
ocular hypotensive activity in animals. Studies in cats 
124 
by Helal et al. demonstrated that intravenous timolol 
decreased IOP by 20% and aqueous humor formation by 62%, 
beginning at 45 to 60 minutes after injection. Liu et 
12 5 
al. ^ also demonstrated that the decrease m aqueous humor 
formation was related to the concentration of timolol per¬ 
fused through the anterior chamber of the cat eye. 
The fact that both ^-adrenergic agonists and antag¬ 
onists act to decrease IOP by the same mechanism of decreas¬ 
ing aqueous humor formation is not consistent with the 
relationship of adrenergic agonist and antagonist seen in 
other tissues. Various explanations for this paradoxical 
situation have been proposed, one being that the 3-adren- 
ergic antagonists may cause a decrease in IOP in a way other 
than the blocking of the (3-adrenergic receptors. This 
view has been dismissed by some on the basis that d- 
propranolol, which has virtually no 3-adrenergic blocking 
activity, also has no ability to decrease IOP.®'7 Recent 
studies demonstrate that this is not the case for all d- 

-21- 
1 p D 
isomers of f3-adrenergic antagonists. Liu and Chioux 
have demonstrated that both 1- and d-timolol are capable 
of decreasing aqueous humor formation without affecting the 
rate of aqueous outflow in the cat. 
98 
The work of Vareilles et al. supports the theory 
that timolol decreases IOP by a mechanism other than (3- 
adrenergic blockade. They demonstrated that timolol, in 
concentrations as low as 0.001$, applied topically, antag¬ 
onized the inhibitory effect of isoproterenol on the water- 
load-induced elevation in IOP; this was felt to be due to 
timolol's ^-adrenergic blocking activity. This study is 
very interesting because it vividly demonstrates that the 
^-antagonistic effects of timolol are present at low con¬ 
centrations (0.001$), but that much greater doses are re¬ 
quired to induce a decrease in IOP (0.5$)* 
9 9 
Schmitt et al.studied several 3-adrenergic antag¬ 
onists and demonstrated that topical application of 0.1$ 
to 1.0$ solutions of propranolol were capable of blunting 
the increase in IOP caused by water-loading in rabbits, 
while oxprenolol and practolol were not. 0.01$ to 1.0$ 
timolol solutions and 1.0$ oxprenolol solutions blunted 
the isoproterenol-induced reduction of elevated IOP in 
water-loaded rabbits; whereas alprenolol, practolol, and 
propranolol at doses of 0.01$ to 1.0$ had no effect. Ox¬ 
prenolol was capable of blocking the effect of 1-isopro¬ 
terenol on IOP in water-loaded rabbits, but had no effect 
on IOP by itself in the same animal model. On the other 
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hand, alprenolol and propranolol did not block the effect 
of isoproterenol on IOP, but did block the elevation of IOP 
induced by water-loading. They also demonstrated that 0.001% 
timolol, 0.01% oxprenolol, and 0.1% propranolol, but not 
alprenolol and practolol, reduced the increase in aqueous 
humor cyclic-AMP that had been induced by isoproterenol. 
Once again, concentrations of timolol, too small to decrease 
IOP, had been shown to effect P-adrener^ic blockade. The 
authors concluded from these findings that there was little 
relationship between a P-adrenergic antagonist's ability 
to block (3 receptors and to decrease IOP. 
. . 126 
Bergammi et al. determined the I^Q for several 
topically-applied ^-adrenergic antagonists in rabbit eyes 
treated with epinephrine. The I^Q is the concentration of 
antagonist needed to inhibit the IOP-lowering effect of 
topical epinephrine by 50%. The I^ of timolol was found 
to be 3 x 10~^%. Other studies in rabbits have demonstrated 
that timolol is not capable of decreasing IOP at this low 
, ,. 95,98 
concentration , y 
129 
Washout studies with timolol suggest that timolol 
applied topically to rabbit eyes inhibits the isoproter¬ 
enol-mediated activation of adenyl cyclase for only 3 to 
5 hours, even though the ability of timolol to decrease 
IOP is of much greater duration. If the ability of timolol 
to decrease IOP were secondary to its effect upon f3-adren- 
ergic receptors, it would be necessary for these receptors 
to be blocked throughout the duration of the effect, accord- 
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ing to the presently accepted model of the action of adren¬ 
ergic antagonists. The fact that timolol does not remain 
at the receptors for an extended length of time argues 
against g-adrenergic blockade as the mechanism by which 
timolol decreases IOP. 
These studies support the position that timolol re¬ 
duces IOP by mechanisms other than 3-adrenergic blockade. 
Several different authors have proposed this explanation 
based on different evidence. J 
The purpose of this study was to estimate the concen¬ 
tration of timolol in the ciliary processes after topical 
administration of the drug in rabbit eyes. Two different 
concentrations of timolol were used; one capable of decreas¬ 
ing IOP, and the other incapable of decreasing IOP. If 
timolol were in fact decreasing IOP by 3-adrenergic antag¬ 
onism, the concentrations of timolol in the ciliary pro¬ 
cesses after topical instillation of both concentrations 
should be close to for timolol binding to the P-adren- 
ergic receptors in this tissue. If this were not the mech¬ 
anism by which timolol is decreasing IOP, and if, as some 
data suggests, timolol lowers IOP at concentrations well 
above those required to achieve complete blockade of cil¬ 
iary process P-adrenergic receptors, then the concentra¬ 
tion of timolol in the ciliary processes should be much 
higher than Kj. 
Preliminary studies to determine the concentrations 
of timolol to be used were conducted in rabbits with a- 
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chymotrypsin-induced increases in IOP. The effect on IOP 
of various concentrations of timolol in these animals was 
to serve as the basis for the selection of the concentra¬ 
tions of timolol to be used in determining the ciliary 
process concentration of timolol after topical application 
of the drug. 
The concentration of timolol in the samples of ciliary 
process, iris, cornea, sclera, and conjunctiva was estimated 
by applying [^H]timolol topically to rabbit eyes and deter¬ 
mining the radioactivity in tissues removed from the eyes 
by liquid scintillation counting. 

MATERIALS AND METHODS 
MATERIALS 
Drugs for in vivo studies 
Timolol maleate as the solid, and [^H]timolol (0.20 mg, 
3.15 mCi in 5 nil ethanol) were generously donated by Merck, 
Sharp, and Dohme of Rahway, New Jersey. Both were the 1- 
isomer. Pentobarbital sodium injection, USP (50 mg/ml, 
Nembutal) was obtained from Abbott Laboratories, North 
Chicago, Illinois. Proparacaine HC1 0.5%> solution (Alcaine), 
and a-chymotrypsin (Zolyse, reconstituted with 5 nil of 
dilutent) were obtained from Alcon Laboratories, Fort Worth, 
Texas. 
Instruments for eye examinations and IOP measurements 
A Haag-Streit slit lamp was used for all biomicroscopic 
examinations. IOP measurements were made with an Alcon 
applanation pneumatonograph previously calibrated by intra¬ 
ocular manometry. 
Materials for determination of concentration of timolol 
in ocular tissues 
Collagenase (160 units/mg solid) was obtained from 
Sigma Chemical Co., St. Louis, Missouri. Protosol (0.5 M)» 
Econofluor Scintillation Cocktail, and the tritium standard 
(2.42 x 10 dpm/ml) were obtained from New England Nuclear, 
Boston. 
Radioactivity was determined in a Nuclear-Chicago Mark 
II Liquid Scintillation System. 
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RESPONSE OF IOP TO TOPICAL TIMOLOL 
Preparation of animals 
Twenty male New Zealand White rabbits, weighing 1.5 
to 2.5 kg each were used in thses studies. The method of 
1 34 
Sears and Sears, with minor modifications, was used to 
induce an increase in IOP in the right eye of the rabbits. 
The eyes of each rabbit were carefully examined with 
the slit lamp to ensure that the eyes were normal. The 
rabbits were placed under general anesthesia with Nembutal, 
1.5 to 2.5 ml, injected into the marginal ear vein, and 
the anesthetized animal was laid on its left side. One 
drop of Alcaine was placed on the right eye and the eye 
proptosed. A 30-gauge needle was placed through the cornea 
into the anterior chamber to serve as a drain for aqueous 
humor and excess a-chymotrypsin during the injection. A 
second needle, attached to a syringe containing 
a-chymotrypsin, was inserted approximately 1 mm posterior 
to the limbus and the needle point situated in the poster¬ 
ior chamber. Care was taken to avoid damaging the lentic¬ 
ular capsule. 0.4 to 0.7 ml of a-chymotrypsin was injected 
into the posterior chamber, with care taken to distribute 
it as evenly as possible. Both needles were then removed, 
the eyelids closed to prevent drying of the eye, and the 
animal allowed to recover from anesthesia. The left eyes 
were left untouched. The animals were returned to their 
cases and allowed to feed and drink as desired. Six weeks 
elapsed before studies were conducted with the animals. 
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Treatment of animals with timolol 
Animals in which the right eye had been treated with 
a-chymotrypsin were selected for these studies by the follow¬ 
ing criteria: 1) IOP in the right eye was significantly el¬ 
evated over the IOP in the left eye. 2) The gross and bio- 
microscopic examination of the eye revealed no inflammation, 
flare, or clouding of the aqueous humor. 3) The animal had 
not been used in a previous study for at least seven days. 
The animals used in the studies were handled very gently to 
avoid exciting them. 
The concentrations of timolol used in this study were 
0.05%, 0.1%, and 0.5%. A 50 pi aliquot of the timolol sol¬ 
ution to be tested was placed in each eye at time zero, and 
measurements of IOP made before, after, and at the time of 
installation of the timolol. The eyes were anesthetized 
with 1 drop of topical Alcaine prior to each measurement of 
IOP. After the IOP had been determined, the Alcaine was 
washed from the eye with normal saline to limit the duration 
of anesthesia. 
Analysis of the data was made with a paired-difference 
t test, comparing the IOP of each eye with the zero-time IOP 
in the ipsilateral eye. The paired-difference t test was 
chosen because it is a much more sensitive test of the stat¬ 
istical significance than other tests utilizing only mean 
values and their standard deviations. 
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CONCENTRATION OF TIMOLOL IN OCULAR TISSUES 
Preparation of C3Hlt imolol 
1.0 ml of L^H^timolol (0.20mg, 3*15 mCi in 5 ml ethanol) 
was mixed with 5 mg of timolol maleate in 3 ml distilled 
water. This solution was lyophilized, and the resulting 
solid redissolved in sterile normal saline to give a 0.5% 
L^H]timolol solution containing 1.7 x 10^ dpm/ml. A 0.05% 
O 
L^H^timolol solution was prepared by making a 1:10 dilution 
of the 0.5% stock solution. The solutions were stored frozen. 
Concentration of timolol in ocular tissues 
Normal male New Zealand White rabbits weighing 1.5 to 
2.5 kg with normal eyes by gross examination were used. The 
rabbits were placed in a plastic restraining box and allowed 
to become accustomed to the box. A 50 hi aliquot of 0.5% or 
0.05% LrH]timolol solution was layered over the left cornea, 
the lids held open for two minutes, and then the eye washed 
with 15 ml of normal saline. The same procedure was then re¬ 
peated for the right eye, and the rabbit was left alone in 
the restaining box. 
The rabbits were killed at 30 minutes after the instal¬ 
lation of 0.5% timolol, and at 30 and 60 minutes after instal¬ 
lation of 0.05% timolol by injecting 5ml Nembutal into the 
marginal ear vein. The right eye was enucleated and placed 
into 30 ml of Hank's balanced salt solution (BSS) on ice. 
The left eye was then enucleated, and samples of cornea, sclera, 
conjunctiva, iris, and ciliary processes removed. The 
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The sclera and conjunctiva samples were taken from the area 
of the insertion of the superior rectus muscle. The ciliary 
processes were isolated by quickly scraping them free from 
the iris. Tissue samples from the left eye were each kept in 
1 ml of BSS or ice until the dissection of the right eye was 
completed. After the dissection of the left eye had been 
completed, the right eye was dissected in a similar manner, 
and each tissue sample placed in 1 ml of BSS or ice until 
weighed. The enucleation and dissection of both eyes was 
completed within 30 minutes of killing the animal. 
The ciliary processes in BSS were centrifuged at 255° 
rpm for 15 to 20 minutes, the supernatant discarded, and the 
net weight of the pellet determined. The other tissues were 
removed from the BSS and weighed at this time. 0.1 ml of 
collagenase (160 u/mg, lmg/ml) was added to each tissue sam¬ 
ple and the samples were allowed to stand a minimum of two 
hours at room temperature. 0.9 nil of Protosol was then added 
and the tissue samples were placed in a swirling water bath 
at 40°C until the tissues were completely dissolved. Colla¬ 
genase was added prior to the addition of Protosol to the 
tissue samples because preliminary studies indicated that 
collagenase greatly facilitated dissolution of the tissue by 
Protosol. 3*° ml of Econofluor was then added to each sample 
and the radioactivity determined with the Mark II liquid 
scintillation counter. 




was determined by adding 10 (a 1 of tritium (2.42 x 10J dpm/ml) 
to each sample as an internal standard and recounting the sam¬ 
ples. The number of moles of timolol per kilogram of tissue 
was calculated from the amount of C^Hjtimolol in the tissue 
samples (dpm), the specific activity of the L^H]timolol, and 
the wet weight of the tissue samples. 

RESULTS 
RESPONSE OF IOP TO TOPICAL TIMOLOL 
50 pi of 0.5$ timolol produced significant decreases in 
IOP in "both the a-chymotrypsin treated eyes and in normal 
eyes. 50 pi of 0.1$ timolol produced occasional significant 
decreases in mean IOP in both eyes. A 50 pi aliquot of 0.03% 
timolol produced a significant decrease in IOP in only the 
a-chymotrypsin treated eyes. (Table 3) 
CONCENTRATION OF TIMOLOL IN OCULAR TISSUES 
The concentration of timolol in ocular tissues deter¬ 
mined with C^H^timolol are shown in Table 4. The concentra¬ 
tions of timolol were always higher in the right eye than in 
the left eye, with the single exception of the concentration 
of timolol in specimens of sclera after the application of 
0.03% timolol. The differences between right and left samples 
of iris and cornea for both concentrations of timolol tested 
were significant at the P < 0.05 level, calculated by the 
paired-difference t test. 
The concentration of timolol in ciliary processes, 3° 
minutes after installation of a 0.3% timolol solution, was 
0.46 ± 0.22 pmoles timolol/kg tissue. The concentration of 
timolol in the ciliary processes 60 minutes after installation 
of a 0.03% solution was 0.21 ± 0.12 pmoles timolol/kg tissue. 
The concentration differences noted between 0.5$ and 0.05$ 
solutions at JO and 60 minutes respectively were statistic¬ 
ally significant for ciliary processes, iris, and cornea, but 
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not for conjunctiva or sclera. No apparent difference exist¬ 
ed between the concentrations of timolol in the various ocul¬ 
ar tissues determined at 30 and 60 minutes after installation 
of 0.05% timolol solution. 

DISCUSSION 
In this study, C^H]timolol was applied topically to both 
eyes of normal rabbits, and the concentration of retained tim¬ 
olol in ocular tissues was determined. No attempt was made 
to determine whether the timolol was actively taken up by a 
receptor in the tissue, or if it had been retained by some 
other mechanism. 
The studies of the response of IOP to topical timolol 
encouraged the use of 0.05$ and 0.5$ L^H]timolol solutions to 
determine the concentration of timolol in ocular tissues; 
0.05$ timolol solution at 60 minutes because of its inability 
to decrease IOP in normal rabbit eyes, and 0.5$ timolol solu¬ 
tion at 30 minutes because of its ability to decrease IOP 
in both normal and a-chymotrypsin treated eyes. The early 
times after installation of the drug were chosen to minimize 
the amount of radioactive yet pharmacologically inactive met¬ 
abolites of timolol present in the tissue. 
Other studies have produced conflicting data about the 
ability of timolol to decrease IOP in normal rabbit eyes. 
98 
Varielle et al. reported a slight decrease m IOP after 
topical administration of 0.01$, 0.1$, and 1.0$ timolol sol¬ 
utions. This response appeared to be independent of dose. 
118 
On the other hand, Radius et al. demonstrated in rabbits 
a decrease in IOP from 28.4 mmHg to 16.2 mmHg 15 minutes af¬ 
ter topical application of 0.5$ timolol solution. The pre¬ 
sent study demonstates a slight yet statistically signifcant 
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decrease in IOP in normal rabbit eyes using 50 p.1 of 0.5% top¬ 
ical timolol. 
After application of 0.5% and 0.05% L"H]timolol solutions, 
the concentration of timolol in iris and cornea in right 
eyes were significantly greater than the concentrations in 
left eyes. The concentration of timolol in the ciliary pro¬ 
cesses and conjunctiva was also higher in the right eyes than 
in the left, altough the differences were not statistically 
significant . This difference is most likely an artifact of 
the method used in enucleating and dissecting the eyes. The 
right eye was always enucleated first and immediately placed 
into 30 ml of BSS on ice: the left eye was then enucleated and 
dissected. Only after the dissection of the left eye had been 
completed was the right eye removed from the BSS and dissect¬ 
ed. The dissection of both eyes was always completed in 30 
minutes or less; it can therefore be estimated that the right 
eye was in the salt solution for about 15 minutes before the 
tissues were dissected free. During this time, uptake of 
timolol may have continued, resulting in higher concentrations 
of timolol in the tissues of the right eye. 
Another important factor is that the tissues of the left 
eye were dissected free and then each specimen was placed in 
1 ml of BSS. The retained timolol would thus have additional 
time to diffuse out of the tissue into the solution. These 
two factors, a result of the procedure employed in the dissec¬ 
tion, are the most likely causes of the right-left differences 
in timolol concentration. 
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This factor - the allowing of any unbound retained timolol 
to diffuse freely out of the tissue into a timolol-free solu¬ 
tion, also argues that the retained timolol is probably also 
bound in some way to the tissue. However, as has been previ¬ 
ously emphasized, no studies of binding of timolol to actual 
receptor sites were performed. 
It is also important to note that the procedure employed 
would lead to underestimation of the concentration of retain¬ 
ed timolol in the tissues. Upon dissection, the tissues were 
placed in 1 ml of BSS, allowing retained timolol to leave 
the tissue and enter the solution. Wet samples for weighing 
may have contained excess water; this would have lead to ov¬ 
erestimation of the tissue weight, thus decreasing the cal¬ 
culated timolol concentration per kilogram of tissue. Addi¬ 
tional uptake in the right eye could possibly lead to over¬ 
estimation of the retained timolol concentration in tissues; 
however, this overestimate in the right eye is averaged with 
the underestimate of timolol in the left eye. This should 
minimize the effect of overestimation of timolol concentra¬ 
tion due to additional time for diffusion after the killing 
of the rabbit. Overall, these estimates of retained timolol 
concentration in ocular tissues in Table 4 are probably un¬ 
derestimates of the true tissue concentrations. 
73 74 
Bromberg et al. J and Gregory et al. estimated Kj for 
binding of timolol to the 3-adrenergic receptors in rabbit 
ciliary processes to be 0.6 x 10-9 Nathanson 
ated Kj to be 2.5 x 10 -9 M. 
t  estim- 
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The concentrations of timolol found in the ciliary pro¬ 
cesses after topical administration of 0.5% L^H]timolol sol¬ 
ution, 50 hi, a dose capable of decreasing IOP in normal eyes, 
was found in this study to be 4.6 x 10 ^ moles/kg of tissue. 
(Table 4) Topical administration of 0.05% L^H]timolol sol¬ 
ution, which had not been capable of decreasing IOP in normal 
eyes, was 2.1 x 10 ' moles/kg of tissue. If the assumption 
is made that the tissue is 100% water, treatment with 0.5% 
and 0.05% timolol solutions resulted in 4.6 x 10-^ M and 2.1 
-7 . . . 
x 10 M, respectively, in the ciliary processes. It should 
be noted that this assumption also results in an underestim¬ 
ate of the molar concentrations of timolol in tissue. These 
2 7 
concentrations are, by a factor of 10 to 10 , greater than 
r? f) 
the Kj for timolol estimated by Nathanson ' , Bromberg et 
7 7 74 
al , and Gregory et all . Therefore, it is evident that the 
concentration of timolol in the ciliary process far exceeds 
the amount necessary to saturate the g-adrenergic receptors 
in this tissue. It is significant that this is true for a 
dose of timolol (0.05%) which does not decrease IOP. 
17 7 
Using the equation of Cheng and Prusoff m the form 
I-0 = ( 1 ) , where I^q is the concentration of timolol 
needed to inhibit 50% of the stimulation of adenyl cyclase by 
epinephrine in the rabbit, LaJ is the concentration of circul¬ 
ating epinephrine in the rabbit (basal concentration 166 pg/ 
ml, or 9*0 x 10-10 M)1^ K 
* act 
is the activation constant for 

-37- 
epinephrine in rabbit ciliary processes (3.6 x and 
Kj is the inhibition constant for timolol (1.2 x 10-9M, the 
mean of values determined by Bromberg, Gregory, and Sears 
' , and Nathanson^ ). Using thses values, for timolol is 
calculated to be 1.2 x 10 ^ M. If Nathanson's value of K 
act 
- 6 76 
for epinephrine (2.35 x 10 M)f is used, is also 1.2 x 
10~9 M. 
The rabbits used in these studies were obviously under 
stress, thus increasing the animals' serum epinephrine levels. 
Unfortunately, the authoer was unable to find values for cir¬ 
culating epinephrine in stressed rabbits. It can be seen by 
examining the equation for the computation of I^Q that, for 
[A] < Kaci_, I^Q approaches Kj. In order to increase I^Q by 
a factor of 10, the concentration of circulating epinephrine 
7 
would have to increase by a factor of 10 . In humans with 
pheochromocytoma, a catacolamine-secreting tumor, the cir- 
2 
culating epinephrine increases only by a factor of 10 , even 
137- 
m pheochromocytoma that secretes epinephrine exclusively 
140 
. If an increase m circulating epinephrine is assumed 
to be the maximum increase experienced by the rabbits in this 
study, then the term (1 + [A]/K ,) increases only slightly, 
aCX 
and the I^Q, calculated using this higher serum epinephrine 
- 9 . 
concentration, is equal to 1.5 x 10 M, almost identical to 
the I^q computed from basal epinephrine levels. 
The concentrations of timolol found in the ciliary pro- 
2 




it would be expected that the 3-adrenergic receptors of the 
rabbit ciliary process are completely blocked after topical 
application of 50 pi of 0.5% and 0.05% timolol. If timolol's 
ability to decrease I0P were a result of g-adrenergic block¬ 
ade, then both 0.5% and 0.05% timolol solutions should have 
caused a decrease in I0P; however, this was not the case. 
These findings add further support to the premise that timolol 
acts to decrease I0P by a mechanism other than 3-adrenergic 
blockade. 
This author was also very much interested in the work by 
128 
Liu and Chiou which suggests that 1- and d-timolol are 
equally effective in decreasing the formation of aqueous hum¬ 
or. These findings are interesting because the d-isomers of 
3-adrenergic antagonists usually have little adrenergic 
blocking activity. If this is the case for d-timolol - 
and there is no reson to suspect that it is not - then further 
research with d-timolol would provide a definitive answer to 
the question: is timolol's ability to decrease I0P the result 
of a mechanism other than P-adrenergic antagonism? 

TABLE 1 
Effects of adrenergic stimulation on 





IOP Aqueous Outflow 
formation facility 
i (delayed onset) (-* 
i (early onset) U) 




i decrease increase no change 
Arrows in parenthesis designate conclusions inferred 
and not actually observed. 
* Too small to alone account for decrease in IOP. 
TABLE 2 
Effects of adrenergic stimulation on 
aqueous humor dynamics in humans 




3 stimulation l i t 
(epinephrine) (a,3 effect) (3 effect) (a effect) 
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